[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-201536-105":59,"doc-detail-201536-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","1786p-effect-of-rapid-ultra-low-prostate-specific-antigen-decline-ul-psa-in-titan-patients","1786P - Effect of rapid ultra-low prostate-specific antigen decline (UL PSA) in TITAN patients","","Background: In TITAN mCSPC patients, 3 months of apalutamide (APA) plus androgen deprivation therapy (ADT) produced rapid and deep PSA decline associated with improved overall survival. Methods: Associations of two ultra-low PSA groups (>0.02 to ≤0.2 ng/mL and ≤0.02 ng/mL) with overall survival, radiographic progression-free survival, time to castration resistance, and time to PSA progression were assessed using landmark analysis, Kaplan-Meier, and Cox models. Results: More APA than placebo achieved ultra-low PSA; rapid deep decline, particularly UL2, corresponded to better long-term outcomes across disease volumes. Conclusions: Findings can inform future mCSPC treatment escalation or de-escalation trial design.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/1786p-effect-of-rapid-ultra-low-prostate-specific-antigen-decline-ul-psa-in-titan-patients/201536/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/1786p-effect-of-rapid-ultra-low-prostate-specific-antigen-decline-ul-psa-in-titan-patients/201536.png","ImageObject",300,407,{"name":92,"@type":93},"Sarah ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-04",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What treatment and patient population were analyzed in this TITAN study?","Question",{"text":112,"@type":113},"The analysis included TITAN metastatic castration-sensitive prostate cancer (mCSPC) patients receiving apalutamide (240 mg/day) or placebo, each with androgen deprivation therapy (ADT).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were ultra-low PSA groups defined, and what endpoints were evaluated?",{"text":117,"@type":113},"Ultra-low PSA was categorized as UL1 (>0.02 to ≤0.2 ng/mL) and UL2 (≤0.02 ng/mL). Endpoints included overall survival, radiographic progression-free survival, time to castration resistance, and time to PSA progression using landmark and survival modeling.",{"name":119,"@type":110,"acceptedAnswer":120},"What was the main finding regarding rapid deep UL PSA and outcomes?",{"text":121,"@type":113},"More patients in the apalutamide arm achieved UL2 and UL1 PSA declines. Rapid and deep UL PSA—most notably UL2—was associated with significantly improved survival outcomes regardless of baseline disease volume.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},201536,1788535125,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":14,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":129,"read_time":24,"preview_page_count":4},962085320529,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","1786P  \nEffect of rapid ultra-low prostate-specific antigen decline (UL PSA) in TITAN patients (pts) with metastatic castrationsensitive prostate cancer (mCSPC) who received apalutamide (APA) plus androgen deprivation therapy (ADT)  \nA.S. Merseburger1 , N. Agarwal2 , A. Bjartell3 , H. Uemura4 , Á . Juárez5 , A. Bha umik6 , J. Boehm7 , N. T ran7 , N. Krochmann8 , M. Nematian9 , S. D. Mundle10 , S. D. Brookman-May11 , S.A. Mccarthy12 , K. N. N. Chi13 , S. Chowdhury14  \n1 Department of Urology , University Hospital Schleswig-Holstein , Lübeck , Germany , 2 Department of Genitourinary Oncology , Huntsman Cancer Institute , University of Utah , Salt Lake City , UT , USA, 3 Department of Uro logical Cancer , Skåne University Hospital , Lund University , Malmo , Sweden , 4 Department of Medicine , Kindai University Faculty of Medicine , Osaka , Japan , 5 Department of Urology , Hospital Universitario de Jerez de la Frontera , Jerez De La Frontera , Spain , 6 US BioStats , Janssen Research & Development , Titusville , NJ , USA, 7 TA Solid Tumors , Janssen Cilag GmbH , Neuss , Germany , 8 MGMT MSA, Janssen Cilag GmbH Germany , Neuss , Germany , 9 Oncology-Solid Tumors , Janssen Cilag GmbH Germany , Neuss , Germany , 10 Global Medical Affairs , Janssen Research & Development , Ra ritan , NJ , USA, 11 Clinical Research Oncology , Janssen Research & Development , Spring House , PA, USA, 12 Compound Development , Janssen Research & Development , Ra ritan , NJ , USA, 13 Department of Medicine , BC Cancer and Vancouver Prostate Centre , Vancouver , BC, Canada14 Department of Uro logical Cancer , Guy ’s , King ’s , and St Thomas ’ Hospitals and Sarah Cannon Research Institute , London , UK  \nBackground  \nIn TITAN mCSPC pts , 3 mos ’ APA + ADT produced rapid and deep ≤0 .2 ng/mL PSA decline that was associated with improved overall survival (OS) (Chowdhury et al , Ann Oncol. 2023) . Here we evaluate the effect of UL PSA on outcomes.  \nMethods  \n525 and 527 pts receiving 240 mg/d APA or placebo (PBO) + ADT were analyzed. Two groups of UL PSA, > 0.02 to ≤0 .2 ng/mL (UL1) and ≤0 .02 ng/mL (UL2) , were assessed for association with OS, radiographic progression-free survival , time to castration resistance , and time to PSA progression using landmark analysis , Kaplan-Meier method , and Cox proportional hazards model.  \nResults  \nOf 515 APA and 520 PBO pts with evaluable UL PSA values , 49% and 17%, respectively , achieved UL2 PSA during the study. By 3 mos , UL1 and UL2 were achieved in 38% and 23% of APA and 15% and 5% of PBO pts. By 6 mos , these values were 29% and 36%(APA) , and 17% and 6%(PBO) . APA pts with UL1/UL2 at 3 mos had lower baseline PSA and higher % of low-volume disease vs PSA>0.2 ng/mL. Pts with UL1/UL2 at 3 or 6 mos had improved long-term outcomes irrespective of volume. Volume-adjusted outcomes were significantly improved in pts with UL1/UL2 achieved at 3 mos (Table) or at 6 mos. At 42 mos ’ follow-up post landmark , survival rate (%[95% CI]) was 89 (81-94) , 81 (75-85) , and 34 (26-43) when UL2 was achieved at 3 mos , after 3 mos , or never after 3 mos and was 89 (83-93) , 77 (70-83) , and 34 (26- 43) when UL2 was achieved at 6 mos , after 6 mos , or never after 6 mos. Survival rate at 42 mos with UL1 , UL2 , or none achieved at any time was 59 (48-68) , 92 (88-95) , and 33 (26-41) . APA safety profile across subgroups was consistent with previous reports.Table: 1786P  \n\n| HR (95% CI) | PSA values achieved at landmark 3 mos vs PSA > 0.2 ng/mL (ref) in APA groupa UL1 (>0.02 to ≤0 .2 ng/mL) UL2 (≤0 .02 ng/mL) |  |\n| --- | --- | --- |\n| OSb 0.46 (0 .31-0.67)\u003Cbr>Radiographic progression-free survival c 0 .54 (0 .35-0.83)\u003Cbr>Time to castration resistanceb 0.56 (0 .39-0.8)\u003Cbr>Time to PSA progressionb 0.51 (0 .34-0.76) |  | 0.24 (0 .13-0.43)\u003Cbr>0.28 (0 .14-0.54)\u003Cbr>0 .2 (0 .11-0 .38)\u003Cbr>0.11 (0 .04-0.27) |\n\na Stratified by disease volume at baseline. b44.0 mos follow-up. c22.7 mos follow-up.  \nConclusions  \nMore TITAN mCSPC pts achie","cbCaiub5p4PTWNA1","https://ap.wps.com/l/cbCaiub5p4PTWNA1","pdf",49112,"English","# Background\n# Methods\n# Results\n## PSA groups and outcomes\n# Conclusions\n# Clinical trial identification\n# Editorial acknowledgement\n# Funding\n# Disclosure","[{\"question\":\"What treatment and patient population were analyzed in this TITAN study?\",\"answer\":\"The analysis included TITAN metastatic castration-sensitive prostate cancer (mCSPC) patients receiving apalutamide (240 mg/day) or placebo, each with androgen deprivation therapy (ADT).\"},{\"question\":\"How were ultra-low PSA groups defined, and what endpoints were evaluated?\",\"answer\":\"Ultra-low PSA was categorized as UL1 (\\u003e0.02 to ≤0.2 ng/mL) and UL2 (≤0.02 ng/mL). Endpoints included overall survival, radiographic progression-free survival, time to castration resistance, and time to PSA progression using landmark and survival modeling.\"},{\"question\":\"What was the main finding regarding rapid deep UL PSA and outcomes?\",\"answer\":\"More patients in the apalutamide arm achieved UL2 and UL1 PSA declines. Rapid and deep UL PSA—most notably UL2—was associated with significantly improved survival outcomes regardless of baseline disease volume.\"}]","1786P - Effect of rapid ultra-low prostate-specific antigen decline (UL PSA) in TITAN patients | PDF"]